Cipla Limited has informed the Exchange regarding a press release dated August 31, 2026, titled "Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)".
Cipla Ltd Press Release Aug 31 2026
Earlier from Cipla
- Cipla Ltd Press Release Jul 23 2026
- Press Release May 13 2026
- Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin HFA
- Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary Fibrosis